Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EVMN vs JBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EVMN Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 1–4 Matrix Metrics)

EVMN Overall Winner 6-Pillar Tally: EVMN 3 – 1 JBIO (2 Tie) Matrix Metrics: EVMN 1 – 4 JBIO

As of Nov 16, 2026, Evommune, Inc. (EVMN) is the stronger overall head-to-head candidate over Jade Biosciences, Inc. (JBIO) in the Tradestie Institutional Equity Comparison Engine, winning 1–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). EVMN carries a Unified Composite Score of 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin), whereas JBIO carries 32.6/100 (SELL) at $15.34 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While JBIO currently prints a higher short-term Unified Composite Score (32.6/100 SELL vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (1–4 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Defensive Composite Rating Caution: Although EVMN compares more favorably head-to-head, both EVMN (30.0/100 SELL) and JBIO (32.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: EVMN trades in a Neutral technical trend (SURGE options phase, RSI 52.2); meanwhile JBIO is in a Breakdown options structure phase (RSI 51.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EVMN vs JBIO
EVMN US Equity Head-to-Head Winner
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap $315.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 118% Vol
Unified Composite Score
30.0 / 100 SELL
Tech 50.0 Fund 35.0 Flow 69.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.2 · SMA20: $6.45 · SMA50: $7.47
JBIO NASDAQ
Jade Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$15.34
-4.99% 1D
Market Cap $1.0B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.32β · 57% Vol
Unified Composite Score
32.6 / 100 SELL
Tech 20.0 Fund 44.0 Flow 73.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 51.0 · SMA20: $15.01 · SMA50: $15.23

6-Pillar Scorecard Institutional Category Breakdown (EVMN 3 – 1 JBIO)

Columns: Metric · EVMN · JBIO
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale JBIO
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $315.5M $1.0B
3. Profitability & Quality EVMN
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -69.5% -89.2%
4. Balance Sheet & Cash Flow EVMN
Cash Generation (TTM) -$75M -$124M
Cash Flow Margin N/A N/A
Net Cash / Leverage $52M Net Cash $107M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EVMN
Options Structure Phase SURGE BREAKDOWN
Current IV / %ile 209.0% (53rd %ile) 377.7% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EVMN (1) vs JBIO (4)
Institutional Metric EVMN JBIO Criterion Row Edge
Market Capitalization
Scale
$315.5M $1.0B Larger Scale JBIO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-69.5% -89.2% Higher ROE EVMN
52-Week Range Position
Momentum
8% ($5–$33) 32% ($10–$28) Stronger Trend JBIO
Beta / 30D Volatility
Risk Regime
1.05β · 118% Vol 1.32β · 57% Vol Lower Realized Risk JBIO
Unified Institutional Score
Composite Signal
30.0 / 100 (SELL) 32.6 / 100 (SELL) Higher Composite JBIO
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$75M ($52M Net Cash) -$124M ($107M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EVMN +23.48 pp
EVMN: +37.33% · JBIO: +13.85%
3M Horizon JBIO +15.19 pp
EVMN: -50.07% · JBIO: -34.88%
6M Horizon JBIO +37.24 pp
EVMN: -67.57% · JBIO: -30.33%
1Y Horizon JBIO +119.45 pp
EVMN: -61.03% · JBIO: +58.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EVMN vs JBIO. Trailing 12-month operating profitability (EVMN 0.0% vs JBIO 0.0%) and valuation multiples (EVMN N/M vs JBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

EVMN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-69.5% · N/M
JBIO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-89.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EVMN SURGE
5d in phase · OBV ACCUMULATION
Current IV 209.0%
IV Percentile 53rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact EVMN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
JBIO BREAKDOWN
141d in phase · OBV ACCUMULATION
Current IV 377.7%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact JBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EVMN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $315.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
JBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.0B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EVMN vs JBIO Key Questions & Quantitative Answers

As of Nov 16, 2026, Evommune, Inc. (EVMN) is the stronger overall head-to-head candidate over Jade Biosciences, Inc. (JBIO) in the Tradestie Institutional Equity Comparison Engine, winning 1–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). EVMN carries a Unified Composite Score of 30.0/100 (SELL) at $7.10 (N/M Forward P/E, 0.0% operating margin), whereas JBIO carries 32.6/100 (SELL) at $15.34 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While JBIO currently prints a higher short-term Unified Composite Score (32.6/100 SELL vs. EVMN 30.0/100 SELL), EVMN captures the overall institutional head-to-head verdict (1–4 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Defensive Composite Rating Caution: Although EVMN compares more favorably head-to-head, both EVMN (30.0/100 SELL) and JBIO (32.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: EVMN trades in a Neutral technical trend (SURGE options phase, RSI 52.2); meanwhile JBIO is in a Breakdown options structure phase (RSI 51.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

JBIO leads the Growth & Scale pillar: EVMN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with JBIO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, EVMN generates N/A in USD-normalized revenue versus N/A for JBIO. In operating R&D and SG&A reinvestment, EVMN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for JBIO.

EVMN and JBIO trade at balanced relative valuation multiples. EVMN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas JBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EVMN (-69.5% ROE) versus JBIO (-89.2% ROE) capital efficiency.

In options market volatility and institutional positioning, EVMN carries 209.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.05β · 118% Vol realized risk). By comparison, JBIO carries 377.7% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.32β · 57% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.